Current antiretroviral therapy has reduced morbidity and mortality of HIV\npatients. However, their induced hepatotoxicity constitutes a risk. In this issue,\nwe report a clinical case of fulminant hepatitis, observed in the HIV unit\nof the hepatogastroenterology department of the General hospital of Loandjili\nin Pointe-Noire. The patient is a 36-year-old female HIV treated with triple-\ndug combination antiretroviral therapies (ART) including one antiprotease\n(ritonavir) and two non-nucleoside reverse transcriptase inhibitors (nevirapine\nand efavirenz). He developed fulminant hepatitis five years after treatment\ninitiation. He succumbed to the side effects. Although antiretroviral\ncombination therapies are the standard of care for HIV infection, increased\nvigilance is warranted to early identify this side effect and adjust treatment in\norder to prevent fatal consequences.
Loading....